Titre : Glucan 1,3-beta-glucosidase

Glucan 1,3-beta-glucosidase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Membrane Attack Complex
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Glucan 1,3-beta-glucosidase : Questions médicales les plus fréquentes", "headline": "Glucan 1,3-beta-glucosidase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Glucan 1,3-beta-glucosidase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-18", "dateModified": "2025-05-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Glucan 1,3-beta-glucosidase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cellulases", "url": "https://questionsmedicales.fr/mesh/D044602", "about": { "@type": "MedicalCondition", "name": "Cellulases", "code": { "@type": "MedicalCode", "code": "D044602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.450.420.200" } } }, "about": { "@type": "MedicalCondition", "name": "Glucan 1,3-beta-glucosidase", "alternateName": "Glucan 1,3-beta-Glucosidase", "code": { "@type": "MedicalCode", "code": "D043326", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Johannes Wagener", "url": "https://questionsmedicales.fr/author/Johannes%20Wagener", "affiliation": { "@type": "Organization", "name": "Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Ludwig-Maximilians-Universität München, Munich, Germany." } }, { "@type": "Person", "name": "Shigekazu Yano", "url": "https://questionsmedicales.fr/author/Shigekazu%20Yano", "affiliation": { "@type": "Organization", "name": "Graduate School of Sciences and Engineering, Yamagata University." } }, { "@type": "Person", "name": "Malgorzata Mikulska", "url": "https://questionsmedicales.fr/author/Malgorzata%20Mikulska", "affiliation": { "@type": "Organization", "name": "Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy." } }, { "@type": "Person", "name": "Malcolm Finkelman", "url": "https://questionsmedicales.fr/author/Malcolm%20Finkelman", "affiliation": { "@type": "Organization", "name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA." } }, { "@type": "Person", "name": "Yonglong Zhang", "url": "https://questionsmedicales.fr/author/Yonglong%20Zhang", "affiliation": { "@type": "Organization", "name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Soluble concentrations of the terminal complement complex C5b-9 correlate with end-organ injury in preeclampsia.", "datePublished": "2022-07-06", "url": "https://questionsmedicales.fr/article/35820290", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.preghy.2022.07.001" } }, { "@type": "ScholarlyArticle", "name": "Increased plasma level of terminal complement complex in AMD patients: potential functional consequences for RPE cells.", "datePublished": "2023-06-08", "url": "https://questionsmedicales.fr/article/37359546", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1200725" } }, { "@type": "ScholarlyArticle", "name": "Lipopolysaccharides and outer membrane proteins as main structures involved in complement evasion strategies of non-typhoidal Salmonella strains.", "datePublished": "2022-08-20", "url": "https://questionsmedicales.fr/article/35998438", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.molimm.2022.08.009" } }, { "@type": "ScholarlyArticle", "name": "Pitfalls in complement analysis: A systematic literature review of assessing complement activation.", "datePublished": "2022-10-18", "url": "https://questionsmedicales.fr/article/36330514", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.1007102" } }, { "@type": "ScholarlyArticle", "name": "Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients.", "datePublished": "2023-05-08", "url": "https://questionsmedicales.fr/article/37244049", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.prp.2023.154519" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Hydrolases", "item": "https://questionsmedicales.fr/mesh/D006867" }, { "@type": "ListItem", "position": 5, "name": "Glycosidases", "item": "https://questionsmedicales.fr/mesh/D006026" }, { "@type": "ListItem", "position": 6, "name": "Glucosidases", "item": "https://questionsmedicales.fr/mesh/D005959" }, { "@type": "ListItem", "position": 7, "name": "Cellulases", "item": "https://questionsmedicales.fr/mesh/D044602" }, { "@type": "ListItem", "position": 8, "name": "Glucan 1,3-beta-glucosidase", "item": "https://questionsmedicales.fr/mesh/D043326" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Glucan 1,3-beta-glucosidase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Glucan 1,3-beta-glucosidase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Glucan 1,3-beta-glucosidase", "description": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?\nQuels tests sont utilisés pour mesurer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des marqueurs biologiques associés à cette enzyme ?\nComment les tests génétiques aident-ils au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Complement+Membrane+Attack+Complex&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Glucan 1,3-beta-glucosidase", "description": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?\nLa déficience peut-elle causer des problèmes immunitaires ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Complement+Membrane+Attack+Complex&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Glucan 1,3-beta-glucosidase", "description": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?\nY a-t-il des mesures préventives pour les symptômes ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation des patients est-elle importante ?\nLes conseils diététiques peuvent-ils prévenir des complications ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Complement+Membrane+Attack+Complex&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Glucan 1,3-beta-glucosidase", "description": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des thérapies alternatives recommandées ?\nLa diététique joue-t-elle un rôle dans le traitement ?\nDes traitements expérimentaux sont-ils disponibles ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Complement+Membrane+Attack+Complex&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Glucan 1,3-beta-glucosidase", "description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle entraîner des infections fréquentes ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être évitées ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Complement+Membrane+Attack+Complex&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Glucan 1,3-beta-glucosidase", "description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque de déficience ?\nLes facteurs environnementaux influencent-ils le risque ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes facteurs socio-économiques influencent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Complement+Membrane+Attack+Complex&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic se fait par des tests enzymatiques et des analyses génétiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer l'activité de l'enzyme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques spécifiques mesurent l'activité de la glucan 1,3-beta-glucosidase dans les échantillons." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, des douleurs abdominales ou des troubles digestifs peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques associés à cette enzyme ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de glucanes dans le sang peuvent servir de marqueurs biologiques." } }, { "@type": "Question", "name": "Comment les tests génétiques aident-ils au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils identifient des mutations spécifiques dans le gène codant pour l'enzyme, confirmant le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, douleurs abdominales, et troubles de la digestion." } }, { "@type": "Question", "name": "La déficience peut-elle causer des problèmes immunitaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une déficience peut affecter le système immunitaire, augmentant la susceptibilité aux infections." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir, bien que moins fréquents, comme des maux de tête." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la déficience." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être gérés, mais la déficience elle-même est généralement permanente." } }, { "@type": "Question", "name": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La déficience est généralement génétique, donc la prévention n'est pas possible." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les symptômes ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des modifications alimentaires et un suivi médical régulier peuvent aider à gérer les symptômes." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils aider à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les porteurs et informer sur les risques." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur la maladie et ses symptômes est cruciale pour une gestion efficace." } }, { "@type": "Question", "name": "Les conseils diététiques peuvent-ils prévenir des complications ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conseils diététiques appropriés peuvent aider à prévenir des complications digestives." } }, { "@type": "Question", "name": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments enzymatiques et des modifications alimentaires." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à gérer les symptômes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments peuvent être prescrits pour soulager les symptômes digestifs et la douleur." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives recommandées ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certaines thérapies alternatives, comme la phytothérapie, peuvent être envisagées, mais avec prudence." } }, { "@type": "Question", "name": "La diététique joue-t-elle un rôle dans le traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation adaptée peut aider à réduire les symptômes et améliorer la qualité de vie." } }, { "@type": "Question", "name": "Des traitements expérimentaux sont-ils disponibles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur des traitements expérimentaux, mais ils ne sont pas encore largement disponibles." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec cette déficience ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications digestives, immunitaires et neurologiques peuvent se développer." } }, { "@type": "Question", "name": "La déficience peut-elle entraîner des infections fréquentes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une déficience en glucan 1,3-beta-glucosidase peut augmenter le risque d'infections." } }, { "@type": "Question", "name": "Y a-t-il des risques de complications à long terme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des complications à long terme peuvent inclure des troubles digestifs chroniques et des infections récurrentes." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être évitées par une gestion proactive des symptômes." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour cette déficience ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques spécifiques." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque de déficience ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'âge peut influencer l'apparition des symptômes, mais la déficience est généralement génétique." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'y a pas de preuves solides que les facteurs environnementaux influencent ce risque." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents médicaux de troubles digestifs peuvent augmenter la suspicion de déficience." } }, { "@type": "Question", "name": "Les facteurs socio-économiques influencent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs socio-économiques peuvent affecter l'accès aux soins, mais pas directement le risque génétique." } } ] } ] }

Sources (10000 au total)

Soluble concentrations of the terminal complement complex C5b-9 correlate with end-organ injury in preeclampsia.

We sought to determine if soluble levels of C5b-9, the terminal complement complex, correlate with end-organ injury in preeclampsia.... Project COPA (Complement and Preeclampsia in the Americas), a multi-center observational study in Colombia from 2015 to 2016, enrolled hypertensive pregnant women into four groups: chronic hypertensio... C5b-9 concentrations in plasma and urine, using enzyme linked immunosorbent assays.... In total, 298 hypertensive participants were enrolled. Plasma and urine C5b-9 levels were measured in all participants and stratified by quartile (Q1-4), from lowest to highest C5b-9 concentration. Pa... We identified a pattern of increased urine and low plasma C5b-9 levels in patients with preeclampsia and end-organ injury. Soluble C5b-9 levels may be used to identify complement-mediated end-organ in...

Increased plasma level of terminal complement complex in AMD patients: potential functional consequences for RPE cells.

Polymorphisms in complement genes are risk-associated for age-related macular degeneration (AMD). Functional analysis revealed a common deficiency to control the alternative complement pathway by risk... Collection of plasma from patients with wet AMD (n = 87: 62% female and 38% male; median age 77 years) and controls (n = 86: 39% female and 61% male; median age 58 years), grouped for risk factor smok... Genotyping, measurement of TCC concentrations, ARPE-19 cell culture, Ca... TCC concentration in plasma, intracellular free Ca... TCC levels in the plasma of AMD patients were five times higher than in non-AMD controls but did not differ in plasma from carriers of the two risk alleles. Complement-evoked Ca... TCC levels were higher in AMD patients but did not depend on genetic risk factors. The Ca...

Lipopolysaccharides and outer membrane proteins as main structures involved in complement evasion strategies of non-typhoidal Salmonella strains.

Non-typhoidal Salmonella (NTS) infections pose a serious public health problem. In addition to the typical course of salmonellosis, an infection with Salmonella bacteria can often lead to parenteral i...

Pitfalls in complement analysis: A systematic literature review of assessing complement activation.

The complement system is an essential component of our innate defense and plays a vital role in the pathogenesis of many diseases. Assessment of complement activation is critical in monitoring both di... We performed a systematic analysis of the current methods used to assess complement components and reviewed whether the identified studies performed their complement measurements according to the reco... A literature search using the Pubmed/MEDLINE database was performed focusing on studies measuring the key complement components C3, C5 and/or their split products and/or the soluble variant of the ter... A total of 92 out of 376 studies were selected for full-text analysis. Forty-five studies (49%) were identified as using the correct sample type and techniques for their complement analyses, while 25 ... A substantial part of the reviewed studies did not use the appropriate sample type for assessing complement activation or did not mention which sample type was used. This deviation from the standardiz...

Synthetic Oligodeoxynucleotide CpG Motifs Activate Human Complement through Their Backbone Structure and Induce Complement-Dependent Cytokine Release.

Bacterial and mitochondrial DNA, sharing an evolutionary origin, act as danger-associated molecular patterns in infectious and sterile inflammation. They both contain immunomodulatory CpG motifs. Inte...

Modeling complement activation on human glomerular microvascular endothelial cells.

Atypical hemolytic uremic syndrome (aHUS) is a rare kidney disease caused by dysregulation of the complement alternative pathway. The complement dysregulation specifically leads to damage to the glome... Endothelial cells were incubated with human test sera and stained with an anti-C5b-9 antibody to visualize and quantify complement depositions on the cells with immunofluorescence microscopy.... First, we showed that zymosan-activated sera resulted in increased endothelial C5b-9 depositions compared to normal human serum (NHS). The levels of C5b-9 depositions were similar between conditionall... In conclusion, we demonstrate a robust and reliable model to adequately measure C5b-9-based complement deposition on human control and patient ciGMVECs. This model can be used to study the pathophysio...

Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies.

Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction (NMJ) of skeletal muscle. Complement activation is one of the mechanisms by which anti-acetylcholine receptor (anti... In this single-center, observational study of 45 patients with anti-AChR-antibody-positive generalized MG, serum concentrations of major components of the complement pathways, including C1q, C5, C5a, ... The patients with MG exhibited lower serum levels of C5 (p = .0001) and higher serum levels of sC5b-9 (p = .004) compared with the control group. At about 6 months (range, 172-209 days) after the star... Herein, we provide evidence for the activation of the classical complement pathway and its association with disease activity in anti-AChR-antibody-positive generalized MG....